FDA Details National Vaccine Plan
Dr. Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, outlined the importance of the Department of Health and Human Services (HHS) National Vaccine Plan, in a FDA blog on March 11, 2014.
Dr. Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, outlined the importance of the Department of Health and Human Services (HHS) National Vaccine Plan, in a FDA blog on March 11, 2014. Midthun points out how crucial vaccines are in protecting public health and discusses FDA’s role in ensuring a stable supply of safe vaccines.
According to Midthun, the National Vaccine Plan plans on developing new vaccines, enhancing the vaccine safety system, supporting enhanced communication regarding vaccine decision-making, ensuring a stable supply of vaccines, and increasing global prevention of disease through vaccination.
The National Vaccine Program Office recently issued the State of the National Vaccine Plan, which details the government’s progress regarding the vaccine plan. Some of the accomplishments listed in the report include the establishment of a new generation of influenza vaccines, new production techniques, and advances in electronic health data. Other accomplishments include the establishment of Vaccines.gov and vaccine promotional materials.
The report states that the National Vaccine Plan will continue in the coming years with more research into new vaccines, extension of monitoring systems, and continued development of communication paths. The report can be found on the HHS website.
Source: FDA.gov
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
